股本结构
单位：万股
| 公告日期 | 2024-02-07 | 2023-11-09 | 2023-11-09 | 2023-08-09 | 2023-08-09 | 2023-05-24 |
|---|---|---|---|---|---|---|
| 证券总股本 | 296.37 | 251.17 | 227.77 | 192.65 | 164.08 | 292.83 |
| 普通股本 | 296.37 | 251.17 | 227.77 | 192.65 | 164.08 | 292.83 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2023-12-31 | 2023-11-07 | 2023-09-30 | 2023-08-07 | 2023-06-30 | 2023-05-25 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2024-02-07 | 296.37 | 未披露 | 定期报告 | 2023-12-31 |
| 2023-11-09 | 251.17 | 未披露 | 定期报告 | 2023-11-07 |
| 2023-11-09 | 227.77 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Issuance of common stock pursuant to at-the market stock sales, net of expenses
Vesting of RSUs
Exercise of pre-funded warrants
|
2023-09-30 |
| 2023-08-09 | 192.65 | 未披露 | 定期报告 | 2023-08-07 |
| 2023-08-09 | 164.08 | 未披露 |
更多>>
From March 31, 2023 to June 30, 2023
Exercise of pre-funded warrants
Vesting of RSUs
Issuance of common stock pursuant to at-the market stock sales, net of expenses
Issuance of common stock in public offering, net of offering costs
|
2023-06-30 |
| 2023-05-24 | 292.83 | 未披露 |
更多>>
Common Stock offered by the company 1,896,286 shares
|
2023-05-25 |
| 2023-05-19 | 103.20 | 未披露 | 定期报告 | 2023-05-18 |
| 2023-05-11 | 98.90 | 未披露 | 定期报告 | 2023-05-08 |
| 2023-04-28 | 94.74 | 未披露 | 定期报告 | 2023-04-24 |
| 2023-04-10 | 93.21 | 未披露 |
更多>>
Agile Therapeutics, Inc. announced that its board of directors approved a 1-for-50 reverse stock split, to be effective 4:00 p.m. on Monday, April 10, 2023.
|
2023-04-11 |
| 2023-04-10 | 4660.51 | 未披露 | 定期报告 | 2023-04-10 |
| 2023-02-09 | 4653.83 | 4.65 | 定期报告 | 2023-02-08 |
| 2023-03-23 | 4297.01 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Issuance of common stock pursuant to at the market stock sales, net of expenses
Conversion of series A convertible preferred stock
Conversion of series B convertible preferred stock
Issuance of common stock in public offering, net of expenses
Vesting of RSUs
Fractional shares retired as a result of reverse split
|
2022-12-31 |
| 2022-11-07 | 4061.45 | 未披露 | 定期报告 | 2022-11-04 |
| 2022-11-07 | 3902.68 | 未披露 |
更多>>
From June 30, 2022 to September 30, 2022
Issuance of common stock pursuant to a public offering, net of expenses
|
2022-09-30 |
| 2022-08-11 | 3902.30 | 未披露 | 定期报告 | 2022-08-10 |
| 2022-07-06 | 3902.68 | 未披露 |
更多>>
1.Securities the company are offering 26,666,666 shares of common stock
2.The number of shares of the company common stock to be outstanding after this offering is based on 12,360,166 shares of the company common stock outstanding as of June 27, 2022
|
2022-07-06 |
| 2022-06-29 | 1236.02 | 未披露 | 定期报告 | 2022-06-27 |
| 2022-05-12 | 454.21 | 未披露 | 定期报告 | 2022-05-09 |
| 2022-04-26 | 366.85 | 未披露 |
更多>>
Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile”), a women's healthcare company, today announced that the Board approved a 1-for-40 reverse stock split, to be effective 5:00 p.m. on Tuesday, April 26, 2022.
|
2022-04-27 |
| 2022-04-26 | 14674.19 | 未披露 | 定期报告 | 2022-04-26 |
| 2022-03-30 | 13461.69 | 未披露 | 定期报告 | 2022-03-25 |
| 2022-03-14 | 12249.19 | 未披露 | 定期报告 | 2022-02-28 |
| 2021-11-02 | 12139.60 | 未披露 | 定期报告 | 2021-10-29 |
| 2021-10-13 | 11959.49 | 未披露 |
更多>>
1.Common stock offered by company 26,666,648 shares.
2.The number of shares of common stock to be outstanding after this offering is based on 92,928,205 shares of common stock outstanding as of June 30, 2021.
|
2021-10-13 |
| 2021-11-02 | 9472.94 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Issuance of common stock pursuant to at-the market stock sales, net of expenses
|
2021-09-30 |
| 2021-07-26 | 9300.00 | 未披露 | 定期报告 | 2021-07-23 |
| 2021-07-26 | 9292.82 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021
Issuance of common stock pursuant to at-the market stock sales, net of expenses
Vesting of RSUs
|
2021-06-30 |
| 2021-05-04 | 8826.37 | 未披露 |
更多>>
from December 31, 2020 to March 31, 2021
Issuance of common stock pursuant to at-the market stock sales, net of expenses
Issuance of common stock upon exercise of stock options
Vesting of RSUs
|
2021-03-31 |
| 2021-03-01 | 8762.89 | 未披露 | 定期报告 | 2021-02-24 |
| 2021-03-01 | 8756.38 | 未披露 |
更多>>
From December 31, 2019 to December 31, 2020
Issuance of common stock in public offering, net of expenses
Issuance of common stock upon exercise of stock options
|
2020-12-31 |
| 2020-11-12 | 8743.46 | 未披露 |
更多>>
From June 30, 2020 to September 30, 2020
Issuance of common stock upon exercise of stock options
|
2020-09-30 |
| 2020-08-11 | 8729.76 | 未披露 |
更多>>
From March 31, 2020 to June 30, 2020
Issuance of common stock upon exercise of stock options
|
2020-06-30 |
| 2020-05-05 | 8721.32 | 未披露 |
更多>>
From December 31, 2019 to March 31, 2020
Issuance of common stock in public offering, net of expenses
Issuance of common stock upon exercise of stock options
|
2020-03-31 |
| 2020-02-25 | 8481.03 | 未披露 |
更多>>
1.Common stock offered by us 15,000,000 shares of common stock
2.The number of shares of our common stock to be outstanding after this offering is based on 69,810,305 shares of our common stock outstanding as of December 31, 2019
|
2020-02-25 |
| 2020-02-20 | 6981.03 | 未披露 |
更多>>
From December 31, 2018 to December 31, 2019
Issuance of common stock in private placement, net of expenses
Issuance of common stock pursuant to at-the-market stock sales, net of expenses
Issuance of common stock upon exercise of stock options
Proceeds from issuance of common stock in public offering, net of expenses
Vesting of RSUs
|
2019-12-31 |
| 2019-10-28 | 5930.21 | 未披露 |
更多>>
from June 30, 2019 to September 30, 2019
Proceeds from issuance of common stock in public offering, net of expenses
Issuance of common stock pursuant to at-the-market stock sales, net of expenses
|
2019-09-30 |
| 2019-08-06 | 5726.39 | 未披露 | 定期报告 | 2019-08-06 |
| 2019-08-01 | 4477.58 | 未披露 | 定期报告 | 2019-07-31 |
| 2019-08-01 | 4463.23 | 未披露 |
更多>>
from March 31, 2019 to June 30, 2019
Issuance of common stock pursuant to at-the-market stock sales, net of expenses
Issuance of common stock upon exercise of stock options
|
2019-06-30 |
| 2019-05-03 | 4374.32 | 未披露 | 定期报告 | 2019-05-02 |
| 2019-04-25 | 4363.14 | 未披露 | 定期报告 | 2019-04-17 |
| 2019-05-03 | 4361.53 | 未披露 |
更多>>
from December 31, 2018 to March 31, 2019
Issuance of common stock in private placement, net of expenses
Issuance of common stock pursuant to at-the-market stock sales, net of expenses
Vesting of RSUs
|
2019-03-31 |
| 2019-03-12 | 4321.44 | 未披露 | 定期报告 | 2019-03-11 |
| 2019-03-04 | 3478.76 | 未披露 | 定期报告 | 2019-03-04 |
| 2019-03-12 | 3437.73 | 未披露 |
更多>>
from December 31, 2017 to June 30, 2018
Vesting of RSUs
|
2018-06-30 |
| 2018-03-12 | 3424.83 | 未披露 | 定期报告 | 2018-03-09 |
| 2018-03-12 | 3418.63 | 未披露 |
更多>>
from December 31, 2016 to November 03, 2017
Vesting of RSUs
Issuance of common stock in public offering, net of expenses
Issuance of common stock upon exercise of options
|
2017-11-03 |
| 2017-11-06 | 3415.80 | 未披露 | 定期报告 | 2017-09-30 |
| 2017-04-24 | 2880.64 | 未披露 | 定期报告 | 2017-04-17 |
| 2017-03-15 | 2877.64 | 未披露 | 定期报告 | 2017-03-10 |
| 2017-03-15 | 2875.97 | 未披露 |
更多>>
from December 31, 2015 to December 31, 2016
Vesting of RSUs
Issuance of common stock in public offering, net of expenses
Exercise of stock options
|
2016-12-31 |
| 2017-01-09 | 2880.00 | 未披露 | 定期报告 | 2016-11-04 |
| 2016-11-07 | 2875.77 | 未披露 | 定期报告 | 2016-09-30 |
| 2016-08-08 | 2875.27 | 未披露 | 定期报告 | 2016-06-30 |
| 2016-05-09 | 2874.27 | 未披露 | 定期报告 | 2016-05-05 |
| 2016-05-09 | 2873.81 | 未披露 | 定期报告 | 2016-03-31 |
| 2016-03-09 | 2873.76 | 未披露 | 定期报告 | 2016-03-04 |
| 2016-03-09 | 2231.56 | 未披露 |
更多>>
from December 31, 2014 to December 31, 2015
Issuance of common stock in Private Placement, net of expenses
Exercise of stock options
|
2015-12-31 |
| 2015-11-09 | 2229.22 | 未披露 | 定期报告 | 2015-09-30 |
| 2015-08-13 | 2227.16 | 未披露 | 定期报告 | 2015-08-12 |
| 2015-08-13 | 2223.81 | 未披露 | 定期报告 | 2015-06-30 |
| 2015-06-19 | 2223.51 | 未披露 | 定期报告 | 2015-06-18 |
| 2015-05-12 | 2220.26 | 未披露 | 定期报告 | 2015-05-11 |
| 2015-04-29 | 2217.26 | 未披露 | 定期报告 | 2015-04-15 |
| 2015-05-12 | 2216.02 | 未披露 | 定期报告 | 2015-03-31 |
| 2015-03-26 | 2215.44 | 未披露 | 定期报告 | 2015-03-16 |
| 2015-03-26 | 1863.49 | 未披露 |
更多>>
from December 31, 2013 to December 31, 2014
Issuance of common stock for employee bonuses
Conversion of preferred stock to common stock
Conversion of notes and accrued interest
Common stock issued in IPO, net of expenses
Exercise of stock options
A 1.4-for-one stock split of our common stock effected on May 7, 2014.
|
2014-12-31 |
| 2014-08-14 | 1859.30 | 未披露 | 定期报告 | 2014-06-30 |
| 2014-05-23 | 1859.21 | 未披露 |
更多>>
The conversion, on a 1.4-for-one basis, of all outstanding shares of convertible preferred stock into shares of common stock upon the closing of this offering.
The expiration without exercise of all outstanding warrants to purchase shares of Series A-1 and Series A-2 convertible preferred stock.
The conversion of all outstanding warrants to purchase shares of Series C convertible preferred stock into warrants to purchase 35,003 shares of common stock upon the closing of this offering.
A 1.4-for-one stock split of our common stock effected on May 7, 2014.
|
2014-05-23 |
| 2014-05-09 | 11.35 | 629.24 |
更多>>
A 1.4-for-one stock split of our common stock effected on May 7, 2014.
|
2014-05-08 |
| 2014-03-17 | 7.40 | 629.24 |
更多>>
from December 31,2012 to December 31,2013
Issuance of Common Stock for employee bonuses
Issuance of common stock upon exercise of options
|
2013-12-31 |
From June 30, 2023 to September 30, 2023
Issuance of common stock pursuant to at-the market stock sales, net of expenses
Vesting of RSUs
Exercise of pre-funded warrants
From March 31, 2023 to June 30, 2023
Exercise of pre-funded warrants
Vesting of RSUs
Issuance of common stock pursuant to at-the market stock sales, net of expenses
Issuance of common stock in public offering, net of offering costs
Common Stock offered by the company 1,896,286 shares
Agile Therapeutics, Inc. announced that its board of directors approved a 1-for-50 reverse stock split, to be effective 4:00 p.m. on Monday, April 10, 2023.
From December 31, 2021 to December 31, 2022
Issuance of common stock pursuant to at the market stock sales, net of expenses
Conversion of series A convertible preferred stock
Conversion of series B convertible preferred stock
Issuance of common stock in public offering, net of expenses
Vesting of RSUs
Fractional shares retired as a result of reverse split
From June 30, 2022 to September 30, 2022
Issuance of common stock pursuant to a public offering, net of expenses
1.Securities the company are offering 26,666,666 shares of common stock
2.The number of shares of the company common stock to be outstanding after this offering is based on 12,360,166 shares of the company common stock outstanding as of June 27, 2022
Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile”), a women's healthcare company, today announced that the Board approved a 1-for-40 reverse stock split, to be effective 5:00 p.m. on Tuesday, April 26, 2022.
1.Common stock offered by company 26,666,648 shares.
2.The number of shares of common stock to be outstanding after this offering is based on 92,928,205 shares of common stock outstanding as of June 30, 2021.
From June 30, 2021 to September 30, 2021
Issuance of common stock pursuant to at-the market stock sales, net of expenses
From March 31, 2021 to June 30, 2021
Issuance of common stock pursuant to at-the market stock sales, net of expenses
Vesting of RSUs
from December 31, 2020 to March 31, 2021
Issuance of common stock pursuant to at-the market stock sales, net of expenses
Issuance of common stock upon exercise of stock options
Vesting of RSUs
From December 31, 2019 to December 31, 2020
Issuance of common stock in public offering, net of expenses
Issuance of common stock upon exercise of stock options
From June 30, 2020 to September 30, 2020
Issuance of common stock upon exercise of stock options
From March 31, 2020 to June 30, 2020
Issuance of common stock upon exercise of stock options
From December 31, 2019 to March 31, 2020
Issuance of common stock in public offering, net of expenses
Issuance of common stock upon exercise of stock options
1.Common stock offered by us 15,000,000 shares of common stock
2.The number of shares of our common stock to be outstanding after this offering is based on 69,810,305 shares of our common stock outstanding as of December 31, 2019
From December 31, 2018 to December 31, 2019
Issuance of common stock in private placement, net of expenses
Issuance of common stock pursuant to at-the-market stock sales, net of expenses
Issuance of common stock upon exercise of stock options
Proceeds from issuance of common stock in public offering, net of expenses
Vesting of RSUs
from June 30, 2019 to September 30, 2019
Proceeds from issuance of common stock in public offering, net of expenses
Issuance of common stock pursuant to at-the-market stock sales, net of expenses
from March 31, 2019 to June 30, 2019
Issuance of common stock pursuant to at-the-market stock sales, net of expenses
Issuance of common stock upon exercise of stock options
from December 31, 2018 to March 31, 2019
Issuance of common stock in private placement, net of expenses
Issuance of common stock pursuant to at-the-market stock sales, net of expenses
Vesting of RSUs
from December 31, 2017 to June 30, 2018
Vesting of RSUs
from December 31, 2016 to November 03, 2017
Vesting of RSUs
Issuance of common stock in public offering, net of expenses
Issuance of common stock upon exercise of options
from December 31, 2015 to December 31, 2016
Vesting of RSUs
Issuance of common stock in public offering, net of expenses
Exercise of stock options
from December 31, 2014 to December 31, 2015
Issuance of common stock in Private Placement, net of expenses
Exercise of stock options
from December 31, 2013 to December 31, 2014
Issuance of common stock for employee bonuses
Conversion of preferred stock to common stock
Conversion of notes and accrued interest
Common stock issued in IPO, net of expenses
Exercise of stock options
A 1.4-for-one stock split of our common stock effected on May 7, 2014.
The conversion, on a 1.4-for-one basis, of all outstanding shares of convertible preferred stock into shares of common stock upon the closing of this offering.
The expiration without exercise of all outstanding warrants to purchase shares of Series A-1 and Series A-2 convertible preferred stock.
The conversion of all outstanding warrants to purchase shares of Series C convertible preferred stock into warrants to purchase 35,003 shares of common stock upon the closing of this offering.
A 1.4-for-one stock split of our common stock effected on May 7, 2014.
A 1.4-for-one stock split of our common stock effected on May 7, 2014.
from December 31,2012 to December 31,2013
Issuance of Common Stock for employee bonuses
Issuance of common stock upon exercise of options